YOU ARE HERE: LAT HomeCollectionsStemcells Inc

Stemcells Inc

September 1, 2005 | From Bloomberg News
StemCells Inc., a biotechnology company developing therapies using cells from adult brain tissue, said it had received a manufacturing license in California that would allow it to process its product here. Locating its processing plant in California will help StemCells improve its chances of tapping into state funding available through Proposition 71, a state law designed to encourage stem cell research, the Palo Alto company said.
February 24, 2001 | Reuters
U.S. researchers have produced laboratory mice with human brain cells, marking a potential step toward developing treatments for human brain disease such as Alzheimer's but promising to fuel fresh debate over bioengineering. The research was done at California biotechnology company StemCells Inc. "We are not re-creating a human brain.
October 22, 2005 | From Associated Press
Federal regulators Thursday approved what would be the first transplant of fetal stem cells into human brains. The transplant recipients will be children who suffer from a rare, fatal genetic disorder. The Food and Drug Administration said that doctors at Stanford University Medical Center could begin the testing on six children afflicted with Batten disease, a degenerative malady that renders its young victims blind, speechless and paralyzed before it kills them.
October 17, 2012 | Michael Hiltzik
StemCells Inc. has a history not much different from those of dozens, even hundreds, of biotech companies all around California. Co-founded by an eminent Stanford research scientist, the Newark, Calif., firm has struggled financially while trying to push its stem cell products through the research-and-development pipeline. It collects about $1 million a year from licensing patents and selling cell cultures but spends well more than $20 million annually on R&D, so it runs deeply in the red. On the plus side, StemCells Inc. has had rather a charmed relationship with the California stem cell program, that $3-billion taxpayer-backed research fund known formally as the California Institute for Regenerative Medicine.
August 27, 2000 | From Dow Jones Newswires
Two days after a ban on federal grants for research on human embryo cells was lifted, shares of Irvine-based Nexell Therapeutics Inc. accelerated their gains Friday, defying the profit-taking that hit the company's peers. Several companies involved in stem cell research, including StemCells Inc., Aastrom Biosciences Inc. and Geron Corp.
December 14, 2012
The California Institute for Regenerative Medicine, the quasi-governmental agency authorized to spend $3 billion in taxpayer money on embryonic stem cell research, deserves praise for commissioning an independent study of its operations by a blue-ribbon committee of the Institute of Medicine, the health arm of the National Academy of Sciences. But the $700,000 spent on the study - funded by donations - will be wasted if the institute's oversight board fails to heed the committee's criticisms, which echo the findings of the Little Hoover Commission and other groups over the years.
December 7, 2012 | By Eryn Brown, Los Angeles Times
The board of California's stem cell funding agency is rife with conflicts of interest and should be restructured to improve the integrity of its grant-making process, according to a new report from independent experts convened by the national Institute of Medicine. The committee found that "far too many" of the board members are from organizations that stand to benefit from the $3 billion the California Institute for Regenerative Medicine is supposed to dole out to researchers over 10 years.
May 25, 2009 | MICHAEL HILTZIK
Dr. Philip H. Schwartz spent six years providing university researchers with neural stem cells cultured by a method he had helped invent at the Salk Institute in La Jolla. He figured this was a win-win. His technique provided biomedical scientists with live tissue, an improvement over the dead cells, harvested from the brains of deceased patients, that had been the standard fare. Science marched ahead, bringing novel neurological applications closer to reality.
Los Angeles Times Articles